TITLE

FDA moves to streamline patient info

AUTHOR(S)
Dickinson, James G.
PUB. DATE
December 2012
SOURCE
Medical Marketing & Media;Dec2012, Vol. 47 Issue 12, p34
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the efforts of the drugs center of the U.S. Food and Drug Administration (FDA) to draft a regulation in order to implement the proposed Patient Medication Information (PMI) sheet in the near future.
ACCESSION #
84294248

 

Related Articles

  • FDA final guidance on 'Dear Healthcare Provider' letters.  // CenterWatch Monthly;Apr2014, Vol. 21 Issue 4, p6 

    The article reports that a guidance document titled "Dear Health Care Provider Letters: Improving Communication of Important Safety Information," has been released by the Food & Drug Administration (FDA). It offers information on the content and format of Dear Healthcare Provider (DHCP) letters...

  • Bill Watch.  // McKnight's Long-Term Care News;Jan2012, Vol. 33 Issue 1, p4 

    The article presents information on various medical bills including a new Senate bill that would provide the U.S. Food and Drug Administration a new recall powers and approval of HR 3094 bill by the House that would grant employers more power against quick union organizing efforts.

  • FDA hands down guidance on mobile apps. Newman, Elizabeth // McKnight's Long-Term Care News;Dec2013, Vol. 34 Issue 12, p30 

    The article focuses on guidance issued by the U.S. Food and Drug Administration on mobile medical applications which are intended for helping patients in self-management of disease, document health condition, and track health information and informs that 100 applications had already been approved.

  • Hamburg Describes Efforts to Develop Medical Countermeasures. Drakulich, Angie // Pharmaceutical Technology;Apr2011, Vol. 35 Issue 4, p26 

    The article reports on the potential contribution of Food and Drug Administration (FDA) to the medical countermeasures for responding to natural and deliberate threats to public health in the U.S. in 2011. It mentions the actions to be carried out by the agency which include its cooperation with...

  • Biosimilars regulations unlikely to unfold soon. DEARMENT, ALARIC // Drug Store News;2/7/2011, Vol. 33 Issue 2, p28 

    The article reports on the repeal of the Patient Protection and Affordable Care Act by the U.S. Congress. It notes that the effort largely is unlikely to succeed, so at least one portion of the healthcare-reform law will remain in effect. Furthermore, it mentions that the Food and Drug...

  • By Creating Impassable Pathway, Biosimilar Law Could be DOA. Thiel, Karl // BioWorld Today;6/1/2010, Vol. 21 Issue 104, p1 

    The article analyzes the biosimilar provisions within the Patient Protection and Affordable Care Act. Cited in the bill are suggestions about what the U.S. Food and Drug Administration (FDA) may or may not request in terms of evidence of similarity but almost all of it depends on the judgment of...

  • Attorney sees FDA, industry avoiding court on IIb issue. McCARTY, MARK // Medical Device Daily;10/11/2010, Vol. 14 Issue 197, p1 

    The article considers the response of the Advanced Medical Technology Association (AdvaMed) to the changes proposed by the U.S. Food and Drug Administration (FDA) for the 510(k) scheme. The association emphasizes the need for the agency to revise the statute to implement the split of class II...

  • Marketers weigh DTC policy pitfalls. Arnold, Matthew // Medical Marketing & Media;Jun2009, Vol. 44 Issue 6, p23 

    The article reports on consumer drug marketers' insights about the Drugs and Therapeutics Committee (DTC) National Conference in April 2009. Jim Davidson of Polsinelli Shughart and the Advertising Coalition said that the advertising fight is not over. Michael McCaughan of Elsevier's Research...

  • Regulatory Update.  // McKnight's Long-Term Care News;Jan2011, Vol. 32 Issue 1, p4 

    The article offers news briefs related to health care regulation in the U.S. including the launch of the multiple chronic condition initiative of the Department of Health and Human Services and the warning of the Food and Drug Administration on the use of needleless and pre-filled glass syringes.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics